

30 January 2015

Market Announcements Platform
Australian Securities Exchange
Level 1, 20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

CORRECTION TO QUARTERLY CASH FLOW REPORT

The Company advises that the Quarterly Cash Flow Report lodged earlier today contained two typographical errors, as follows:

- Note 1.21 “Cash at beginning of quarter/YTD” should have read “1,501”; and
- Note 1.23 “Cash at end of quarter” should have read “1,119”.

A revised Appendix 4C is attached.

Yours faithfully



Lee Mitchell
Company Secretary



ASX Announcement

For immediate release

30 January 2015

BLUECHIIP LIMITED DECEMBER 2014 QUARTERLY CASH FLOW REPORT

Bluechiip Limited (ASX: BCT) today released its quarterly cash flow report for the period ended 31 December 2014.

Highlights for the quarter:

- Share Purchase Plan (**SPP**) receipts of \$623,000 (before fees) from a total of \$763,000 (\$140,000 received in prior quarter);
- Sales receipts generated from maiden sales made to distributors in South Korea and Japan;
- Cash on hand at 31 December of \$1.12m.

Commentary

Net operating cash outflow for the December 2014 quarter was \$889,899 representing an average monthly operating net cash outflow of \$296,633 (previous four quarters to September 2014 averaged \$245,879 per month). The increase in operating net cash outflow is mainly attributable to the payment of \$323,659 to a major supplier for inventory of tags.

There was no investing cash flow for the December 2014 quarter.

The net cash inflow from financing activities was \$508,594 attributable to proceeds from SPP of \$623,000 after defraying share issue costs of \$114,406 for this quarter's SPP and the prior quarter's Placement. \$140,000 was received in the previous quarter from this SPP.

During the quarter, further commercial and validation activities were undertaken including:

- The establishment of a test and evaluation agreement with SIAD Group in Italy to integrate the Bluechiip Crytag into SIAD's cryobags which are used to store cord blood and other biological products.
- The establishment of Distribution Agreements in Asia with:
 - NPO Bio Bank Support Organisation to sell the Bluechiip product range for biobanking and other life science related markets in Japan
 - Glory Biotech Corp to sell the Bluechiip product range for biobanking and other life science related markets in Korea
 - Axon Scientific Sdn Bhd to sell the Bluechiip product range for biobanking and other life science related markets in Malaysia

In reviewing the company's liquidity and cash flow, the directors note that the company:

- (a) expects sales, licensing and royalty receipts from customers over the coming months; and
- (b) has 10.95M options issued to shareholders, with an exercise price of \$0.13 per option which expires on 31 March 2015

END.

For more information:

Iain Kirkwood
Non Executive Chairman
Ph: +61 408 473 496
iain.kirkwood@bluechiip.com

Andrew McLellan
Managing Director / CEO
Ph: +61 3 9763 9763
andrew.mclellan@bluechiip.com

About Bluechiip Limited:

Bluechiip has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip[®] technology does not. Unlike labels, barcodes and RFID, the bluechiip[®] technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip[®] technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip[®] offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip[®] tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip[®] technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at www.bluechiip.com

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity

BLUECHIIP LTD

ABN

79 104 795 922

Quarter ended ("current quarter")

31 DECEMBER 2014

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter	Cumulative to
	\$A'000	31 December 2014 \$A'000
1.1 Receipts from customers	21	43
1.2 Payments for:		
(a) staff costs	(220)	(449)
(b) advertising and marketing	(14)	(34)
(c) research and development	(370)	(574)
(d) leased assets	(3)	(6)
(e) other working capital	(352)	(632)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	9	13
1.5 Interest and other costs of finance paid	-	(15)
1.6 Income taxes paid	-	-
1.7 Other:		
- GST refunds	38	59
- Income tax refund	0	625
- Government grants	-	-
Net operating cash flows	(891)	(970)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter	Cumulative to
		\$A'000	31 December 2014 \$A'000
1.8	Net operating cash flows (carried forward)	(891)	(970)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other	-	-
	Net investing cash flows	-	-
1.14	Total operating and investing cash flows	(891)	(970)
Cash flows related to financing activities			
1.15	Net proceeds from issuance of shares, options, etc via private placement net of costs	509	1,729
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	235
1.18	Repayment of borrowings	-	(486)
1.19	Dividends paid	-	-
1.20	Others – Other material expenditure	-	-
	Net financing cash flows	509	1,478
	Net increase (decrease) in cash held	(382)	508
1.21	Cash at beginning of quarter/year to date	1,501	611
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	1,119	1,119

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(35)
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	<p>Item 1.2(c): Included in the Research & Development was a payment of AUD\$323,659 (USD280,000) to a major supplier for inventory of tags..</p> <p>Item 1.15 This was in relation to the net proceeds from Share Purchase Plan ("SPP") of AUD\$623,000 (before fees) of which AUD\$140,000 was received in September 2014 pursuant to the SPP carried out in September 2014.</p> <p>Item 1.24: Directors fees.</p>	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

None.

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

None.

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	17	50
3.2	Credit standby arrangements	None	Not applicable
3.3	Credit card facility	None	Not applicable

Item 3.1 This amount is in relation to loan facilities for premium insurance and IT server financing.

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,119	611
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	1,119	611

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	None	None
5.2 Place of incorporation or registration	Not applicable	Not applicable
5.3 Consideration for acquisition or disposal	Not applicable	Not applicable
5.4 Total net assets	Not applicable	Not applicable
5.5 Nature of business	Not applicable	Not applicable

Compliance statement

- This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- This statement does give a true and fair view of the matters disclosed.



Andrew McLellan
Managing Director

Date: 30 January 2015

+ See chapter 19 for defined terms.